Remove whats-the-current-state-of-aesthetic-medicine
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

The action was held from 26 to 28 September 2023, at the city’s international entry points. The action was held from 26 to 28 September 2023, at the city’s international entry points. The products found, subject to retention and seizure, were retained by the Federal Revenue Service. and Biometik Indústria e Comércio de Cosméticos.

FDA 52
article thumbnail

8 benefits of Telehealth

Healthcare IT News - Telehealth

The COVID-19 pandemic has been an eye-opener for what really matters in both personal and professional life. In a survey based in the US, patients that experienced telehealth visits highly rated this type of healthcare (recommendations: > 80%) 5,6 , stating it was beneficial for their mental health as well.

COVID-19 176
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – July and August 2023

SQA

The inspection was motivated by complaints received by health surveillance agencies located in different Brazilian states, which reported on irregularities related to the composition of the companies’ products and divergences related to the labeling information of manufacturers and those responsible for the products.

FDA 40
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – July/August

SQA

Health Canada is warning consumers about counterfeit BTNX Rapid Response COVID-19 antigen rapid test kits (25-pack boxes) found in Ontario. The counterfeit devices were sold online by a distributor named Healthful Plus without the required license to import, distribute, or sell medical devices in Canada. device identifier “COV-19C25.”

article thumbnail

SQA Regulatory Surveillance Summary | December 2020 –

SQA

Inception Impact Assessment for the Initiative to Revise the European Legislation on Medicines for Children and Rare Diseases, Feedback Period: 25 November 2020 to 06 January 2021. These groups have timely access to medicines. European Medicines Agency (EMA). The first step is an inception impact assessment (roadmap).